Non-Hodgkin Lymphoma
Researchers reviewed data on gender, race/ethnicity, zip codes to estimate poverty level, and other factors.
Orelabrutinib monotherapy may be an option for relapsed/refractory Waldenström’s macroglobulinemia.
The U.S. Food and Drug Administration cleared an investigational new drug application for ACE1831, an anti-CD20 armed ...
Advertisement
Lisaftoclax induced responses in patients with a variety of relapsed/refractory malignancies, including NHL and CLL.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use recommended the conditional approval ...
Epcoritamab is a subcutaneous CD3/CD20 bispecific antibody that induces anti-tumor activity across B-cell NHL subtypes.
Advertisement
Autologous hematopoietic stem cell transplantation improved survival outcomes for certain patients younger than 65.
CAR T-cell dysfunction marked by TIGIT expression may be driving poor response to therapy in patients with non-Hodgkin ...
Long-term lymphoma survivors who underwent transplant had impaired health-related quality of life.
Patients with different subtypes of B-cell non-Hodgkin lymphoma experience different treatment outcomes.
The FDA cleared the investigational therapy GDA-201 for lymphoma.
Certain CD19 chimeric antigen receptor (CAR) T-cell products were associated with different levels of adverse events and ...
The FDA granted Fast Track Designation to Adicet Bio’s ADI-001, an investigational therapy targeting CD20 for the potential ...
Even after COVID-19 vaccination, non-Hodgkin lymphoma or CLL patients had low antibody binding and live-virus neutralization.
Immune checkpoint inhibitors can lower the risk of developing neurologic adverse events (NAEs) more than other cancer ...
The allogeneic dual CAR T-cell product demonstrated preclinical activity for patients with relapsed or refractory non-Hodgkin ...
The FDA placed a partial clinical hold on trials evaluating umbralisib and ublituximab in CLL and non-Hodgkin lymphoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.